Your browser does not support JavaScript!

Αρχική    Detection of KRAS G12/G13 Mutations in Cell Free-DNA by Droplet Digital PCR, Offers Prognostic Information for Patients with Advanced Non-Small Cell Lung Cancer  

Αποτελέσματα - Λεπτομέρειες

Προσθήκη στο καλάθι
[Προσθήκη στο καλάθι]
Κωδικός Πόρου https://doi.org/10.3390/cells9112514
Τίτλος Detection of KRAS G12/G13 Mutations in Cell Free-DNA by Droplet Digital PCR, Offers Prognostic Information for Patients with Advanced Non-Small Cell Lung Cancer
Συγγραφέας Michaelidou, Kleita
Συγγραφέας Koutoulaki, Chara
Συγγραφέας Mavridis, Konstantinos
Συγγραφέας Vorrias, Eleftherios
Συγγραφέας Papadaki, Maria A.
Συγγραφέας Koutsopoulos, Anastasios V.
Συγγραφέας Mavroudis, Dimitrios
Συγγραφέας Agelaki, Sofia
Περίληψη KRAS mutations are found in approximately one third of non-small cell lung cancer (NSCLC) patients. In this study, we aim to investigate whether KRAS G12/G13 mutant allele fraction (MAF) in cell-free DNA (cfDNA) can provide meaningful prognostic information in NSCLC. Multiplex droplet-digital PCR was used to quantitatively assess KRAS G12/G13 MAF in cfDNA from 114 pre-treated advanced disease NSCLC patients. In 14 patients, changes in KRAS G12/G13 MAF were longitudinally monitored during treatment. Plasma KRAS G12/G13 status was associated with poor patients’ outcome in terms of progression-free survival (PFS) (p < 0.001) and overall survival (OS) (p < 0.001). In multivariate analysis, the detection of plasma KRAS mutations was an independent predictor of adverse PFS (HR = 3.12; p < 0.001) and OS (HR = 2.53; p = 0.002). KRAS G12/G13 MAF at first treatment evaluation (T1) was higher (p = 0.013) among patients experiencing progressive disease compared to those with disease control, and increased KRAS MAF at T1 was associated (p = 0.005) with shorter PFS. On the contrary, no association was observed between tissue KRAS mutation status and patients’ prognosis. Our results show that ddPCR-based detection of KRAS G12/G13 mutations in plasma could serve as an independent biomarker of unfavorable prognosis in NSCLC patients. Changes in KRAS MAF can provide valuable information for monitoring patient outcome during treatment.
Γλώσσα Αγγλικά
Θέμα Liquid biopsy
Molecular testing
NSCLC
Prognostic biomarker
ctDNA
ddPCR
Ημερομηνία έκδοσης 2020-11-20
Συλλογή   Σχολή/Τμήμα--Ιατρική Σχολή--Τμήμα Ιατρικής--Δημοσιεύσεις
  Τύπος Εργασίας--Δημοσιεύσεις
Σημειώσεις European Commission Horizon 2020-Research and Innovation Program H2020-FETOPEN-1-2016-2017 (GA NUMBER-737212-Capturing non-Amplified Tumor Circulating DNA with Ultrasound Hydrodynamics (CATCH-U-DNA)).
Δικαιώματα χρήσης
Creative Commons License
Εμφανίσεις 3167

Ψηφιακά τεκμήρια
No preview available

Κατέβασμα Εγγράφου
Προβολή Εγγράφου
Εμφανίσεις : 23